Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Ingrid Jyssum, Johanna Elin Gehin, Joseph Sexton, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 6, pp. 1746-1755
Open Access | Times Cited: 9

Showing 9 citing articles:

Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: “early therapeutic drug monitoring of adalimumab”
Patricia Ortiz-Fernández, Carles Iniesta Navalón, Elena Urbieta-Sanz, et al.
Clinical Rheumatology (2025)
Open Access
Therapeutic drug monitoring and neutralizing anti-drug antibody detection to optimize TNF-alpha inhibitor treatment for uveitis
H Chen, Jenny Shunyakova, Amit K. Reddy, et al.
Frontiers in Ophthalmology (2025) Vol. 5
Open Access
Age as a Predictor of Serum Tumor Necrosis Factor Antagonist Drug and Antidrug Antibody Concentrations in Inflammatory Bowel Disease—A Nationwide Cohort Study
Mohammad Shehab, Fatema Alrashed
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1057-1057
Open Access
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
Josef S Smolen, Peter C. Taylor, Yoshiya Tanaka, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 11, pp. 3015-3024
Open Access | Times Cited: 3
Imagining the severe asthma decision trees of the future
Arnaud Bourdin, P Bardin, Pascal Chanez
Expert Review of Respiratory Medicine (2024) Vol. 18, Iss. 8, pp. 561-567
Closed Access
Novel insights into the management of rheumatoid arthritis: one year in review 2024
Emanuele Molteni, Antonella Adinolfi, Valentina Bondi, et al.
Clinical and Experimental Rheumatology (2024)
Open Access
Biological material for biomarker research in spondyloarthritis: mapping the availability in European rheumatology registries
Bente Glintborg, Mikkel Østergaard, Jacob Brauner Jørgensen, et al.
Lara D. Veeken (2024) Vol. 64, Iss. 1, pp. 374-376
Open Access
Quantitative evaluation of adalimumab and anti-adalimumab antibodies in sera using a surface plasmon resonance biosensor
Andrea Di Santo, Matteo Accinno, Fosca Errante, et al.
Clinical Biochemistry (2024) Vol. 133-134, pp. 110838-110838
Closed Access
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
Johanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, et al.
RMD Open (2024) Vol. 10, Iss. 4, pp. e004888-e004888
Open Access
Page 1

Scroll to top